A Phase 1, Randomized, Double-blind, Multiple-dose Study to Evaluate the Pharmacokinetics of AMG 133 Administered Subcutaneously in Subjects With Overweight or Obesity
Latest Information Update: 23 May 2025
At a glance
- Drugs Maridebart cafraglutide (Primary)
- Indications Obesity
- Focus Pharmacokinetics
- Sponsors Amgen
Most Recent Events
- 23 May 2025 New trial record